ASH 2022 | Update on KOMET-001: identifying the optimal dose of ziftomenib for patients with R/R AML
Harry Erba, MD, PhD, Duke University, Durham, NC, outlines preliminary data from an ongoing Phase I/II study of ziftomenib in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) (NCT04067336). So far, the Phase Ia results demonstrate a manageable safety profile and preliminary efficacy of ziftomenib in patients with AML. The phase Ib study determined the optimal biologically active dose for the inhibitor and suggested that with appropriate differentiation syndrome management, ziftomenib is well tolerated. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Gilead/Forty Seven: Research Funding; Forma Therapeutics: Research Funding; Kura Oncology: Consultancy, Research Funding; Trillium Therapeutics: Consultancy; Janssen Oncology: Consultancy; Daiichi Sankyo: Consultancy, Research Funding; ImmunoGen: Consultancy, Research Funding; Glycomimetics: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Jazz Pharmaceuticals: Consultancy, Research Funding, Speakers Bureau; Incyte: Consultancy, Speakers Bureau; MacroGenics: Consultancy, Research Funding; Covance (Abbvie): Consultancy, Other: Independent Review Committee, Research Funding; Novartis: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy; PTC therapeutics: Research Funding; ALX Oncology: Research Funding; Takeda: Consultancy; Celgene: Consultancy, Other, Speakers Bureau; Astellas Pharma: Consultancy; Amgen: Consultancy, Research Funding; Agios: Consultancy, Research Funding, Speakers Bureau; Abbvie: Consultancy, Research Funding, Speakers Bureau; Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau
